The study indicates that effective LA reverse remodeling, associated with lower galectin-3 levels, could improve clinical outcomes in patients with dilated cardiomyopathy, underscoring the importance of galectin-3 as a biomarker for therapeutic strategies and prognosis in heart failure management. The gene discussed is LGALS3; the disease is dilated cardiomyopathy.